Cresco Labs Inc.

CNSX:CL Stock Report

Market Cap: CA$562.0m

Cresco Labs Valuation

Is CL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CA$4.34
Fair Value
71.0% undervalued intrinsic discount
7
Number of Analysts

Below Fair Value: CL (CA$1.26) is trading below our estimate of fair value (CA$4.34)

Significantly Below Fair Value: CL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CL?

Key metric: As CL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CL. This is calculated by dividing CL's market cap by their current revenue.
What is CL's PS Ratio?
PS Ratio0.4x
SalesUS$726.35m
Market CapUS$391.40m

Price to Sales Ratio vs Peers

How does CL's PS Ratio compare to its peers?

The above table shows the PS ratio for CL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
VRNO Verano Holdings
0.5x3.2%CA$631.4m
GUD Knight Therapeutics
1.5x6.5%CA$534.3m
CPH Cipher Pharmaceuticals
9.1x14.1%CA$345.5m
ACB Aurora Cannabis
1x10.7%CA$310.4m
CL Cresco Labs
0.4x1.2%CA$562.0m

Price-To-Sales vs Peers: CL is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does CL's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

26 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.1x4.0%US$50.19m
TIUM.U Cansortium
0.2xn/aUS$22.56m
RWB Red White & Bloom Brands
0.2xn/aUS$14.74m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
CL 0.4xIndustry Avg. 0.8xNo. of Companies26PS012345+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CL is good value based on its Price-To-Sales Ratio (0.4x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is CL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: CL is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$1.26
CA$3.74
+197.2%
29.0%CA$6.18CA$2.80n/a7
Jan ’26CA$1.32
CA$3.71
+180.8%
28.7%CA$6.10CA$2.80n/a7
Dec ’25CA$1.65
CA$3.77
+128.5%
28.2%CA$6.01CA$2.76n/a7
Nov ’25CA$2.14
CA$4.63
+116.6%
15.7%CA$5.99CA$3.80n/a7
Oct ’25CA$2.22
CA$4.61
+107.6%
15.1%CA$5.93CA$3.71n/a8
Sep ’25CA$2.10
CA$6.30
+200.1%
75.4%CA$19.61CA$3.74n/a9
Aug ’25CA$2.20
CA$6.41
+191.5%
74.7%CA$19.86CA$3.81n/a9
Jul ’25CA$2.14
CA$6.67
+211.6%
73.7%CA$19.57CA$4.00n/a8
Jun ’25CA$2.62
CA$6.37
+143.2%
74.4%CA$19.66CA$3.78n/a9
May ’25CA$2.98
CA$5.92
+98.7%
71.7%CA$17.67CA$3.26n/a9
Apr ’25CA$3.04
CA$5.43
+78.7%
52.5%CA$13.12CA$3.27n/a9
Mar ’25CA$2.37
CA$5.02
+112.0%
58.5%CA$13.02CA$2.65n/a9
Feb ’25CA$3.14
CA$4.98
+58.6%
58.6%CA$12.93CA$2.63n/a9
Jan ’25CA$1.79
CA$4.99
+179.0%
59.5%CA$13.14CA$2.68CA$1.329
Dec ’24CA$2.40
CA$4.99
+108.1%
59.5%CA$13.14CA$2.68CA$1.659
Nov ’24CA$1.65
CA$5.30
+221.2%
80.8%CA$17.12CA$2.31CA$2.149
Oct ’24CA$2.72
CA$5.21
+91.6%
80.4%CA$16.77CA$2.26CA$2.229
Sep ’24CA$2.30
CA$4.83
+109.8%
90.3%CA$16.80CA$1.51CA$2.109
Aug ’24CA$2.11
CA$5.19
+146.1%
80.1%CA$16.55CA$2.02CA$2.209
Jul ’24CA$1.98
CA$5.15
+160.2%
79.7%CA$16.38CA$2.17CA$2.149
Jun ’24CA$2.24
CA$3.87
+73.1%
30.1%CA$5.73CA$2.24CA$2.628
May ’24CA$2.09
CA$5.94
+184.4%
76.4%CA$18.13CA$2.22CA$2.989
Apr ’24CA$2.17
CA$6.47
+198.3%
66.4%CA$18.09CA$2.21CA$3.0411
Mar ’24CA$2.37
CA$8.49
+258.1%
43.7%CA$18.17CA$2.75CA$2.3712
Feb ’24CA$2.46
CA$8.86
+260.1%
37.9%CA$17.91CA$4.77CA$3.1412
Jan ’24CA$2.45
CA$9.16
+274.0%
34.4%CA$17.98CA$4.79CA$1.7912
Analyst Price Target
Consensus Narrative from 7 Analysts
CA$3.74
Fair Value
66.3% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 02:30
End of Day Share Price 2025/01/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cresco Labs Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Capital Markets
Kenric TygheATB Capital Markets